

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC., WOCKHARDT BIO AG, and
AMNEAL PHARMACEUTICALS LLC,
Petitioners,

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

Case IPR2015-00554¹
Patent 7,668,730

**PETITIONERS' RESPONSE TO PATENT OWNER REQUEST FOR
REHEARING PURSUANT TO 37 C.F.R. § 42.71(d)**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

¹ Case IPR2015-01818 has been joined with this proceeding.

TABLE OF CONTENTS

	Page
I. INTRODUCTION AND STATEMENT OF RELIEF REQUESTED . Error! Bookmark not defined.	
II. LEGAL STANDARD Error! Bookmark not defined.	
III. PATENT OWNER HAS FAILED TO PROVE THAT THE BOARD OVERLOOKED OR MISAPPREHENDED ANY EVIDENCE THAT SHOULD MODIFY ITS FINAL CLAIM CONSTRUCTIONS Error! Bookmark not defined.	
A. “the prescription requests containing information identifying patients” Error! Bookmark not defined.	
B. “the prescription requests containing information identifying . . . various credentials of the any and all medical doctors” Error! Bookmark not defined.	
IV. CONCLUSION..... Error! Bookmark not defined.	

I. INTRODUCTION AND STATEMENT OF RELIEF REQUESTED

Pursuant to the Board's e-mail authorization on September 6, 2016 (*see* Exhibit 1062), Petitioners Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc. (collectively, "Petitioners") submit this opposition to Patent Owner's Request for Rehearing Pursuant to 37 C.F.R. § 42.71(d) (Paper 69).

Patent Owner's Request does not provide a proper basis for rehearing, but instead merely reiterates Patent Owner's rejected arguments and evidence to import certain limitations into the claims. The Board's Final Decision (Paper 68) explicitly acknowledged and correctly refuted these arguments and evidence based on the governing intrinsic evidence, in holding claims 1–11 of U.S. Patent No. 7,668,730 ("the '730 patent") unpatentable as obvious over the Advisory Committee Art (Exs. 1003–1006) (the "ACA"). Patent Owner's Request for Rehearing should therefore be denied.

II. LEGAL STANDARD

In a request for rehearing, the dissatisfied party "must specifically identify all matters the party believes the Board misapprehended or overlooked, and the place where each matter was previously addressed in a motion, an opposition, or a reply." 37 C.F.R. § 42.71(d). "The burden of showing a decision should be modified lies with the party challenging the decision." *Id.*

III. PATENT OWNER HAS FAILED TO PROVE THAT THE BOARD OVERLOOKED OR MISAPPREHENDED ANY EVIDENCE THAT SHOULD MODIFY ITS FINAL CLAIM CONSTRUCTIONS.

“A Request for Rehearing is not an opportunity to re-argue old arguments” *Histologics, LLC v. CDX Diagnostics, Inc. et al.*, IPR2014-00779, slip op. at 4 (PTAB Oct. 16, 2014) (Paper 9) (citing Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,768 (Aug. 14, 2012)). Yet that is precisely what Patent Owner’s Request seeks to do here. Patent Owner simply re-argues that exemplary embodiments of “information identifying the patient” and “various credentials” should limit the claims—arguments that the Board squarely addressed and rejected. And while Patent Owner highlights certain specification excerpts and/or expert testimony, the Board already considered and refuted that evidence in its Final Decision. The proper course for Patent Owner here “is to appeal, not to file a request for rehearing to re-argue issues that have already been decided.” *SAP Am., Inc. v. Versata Dev. Gr., Inc.*, CBM2012-00001, slip op. at 5 (PTAB Sept. 13, 2013) (Paper 81).

A. “the prescription requests containing information identifying patients”

Patent Owner first argues that the Board overlooked portions of the specification “separate and apart from Figure 9” and certain expert testimony on information “to identify the narcoleptic patient,” which Patent Owner uses to justify its limiting construction of “the prescription requests containing information

identifying patients.” (Request at 4–6 (citing Ex. 1001 at 4:20–22; Ex. 2046 at ¶¶ 43–44; Ex. 2044 at 97:11–98:5, 99:18–100:10).) This is incorrect.

To the contrary, the Final Decision’s claim construction analysis for this term begins by explicitly and repeatedly acknowledging Patent Owner’s arguments and evidence, including the exact specification excerpt and expert testimony of Dr. DiPiro and Dr. Valuck on which Patent Owner’s Request relies. (Final Decision at 18 (citing Ex. 2046 at ¶¶ 39–44; Ex. 1001 at 4:8–22; Ex. 2044 at 97:11–98:5, 99:18–100:10); *id.* (citing Ex. 1001 at 4:20–22; Ex. 2044 at 97:11–23, 99:18–100:10).) The Board did not “overlook” this evidence and consider only Figure 9 of the specification, as Patent Owner suggests. (*See* Request at 3.) It simply disagreed with Patent Owner on what this evidence means for claim construction.

Confirming that the final claim construction was not based solely on the rejection of Patent Owner’s arguments as to Figure 9, the Final Decision states that “*nothing* in the specification suggests that excluding one or more pieces of information in the list of a ‘patient’s name, social security number, date of birth, sex, and complete address information, including city, state, and zipcode,’ as proposed by Patent Owner, means that a prescription fails to contain ‘information identifying the patient,’ as recited in the claims.” (Final Decision at 19 (emphasis added).) The Board made clear that this controlling understanding of the specification refuted Patent Owner’s arguments and supporting evidence to import any such limitations

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.